Horizon Discovery offers CHOSOURCE™ platform for COVID-19-related therapeutics and diagnostics

- Special licensing terms enable rapid access to CHOSOURCE platform to streamline SARS-CoV-2 therapeutic development and production processes - Supports global efforts to develop therapeutics, diagnostic assay components and vaccines to combat the COVID-19 Coronavirus pandemic

Horizon Discovery

Horizon Discovery Group plc (LSE: HZD) (“Horizon”, “the Company” or “the Group”), a global leader in the application of gene editing and gene modulation for cell line engineering, today announced special commercial licensing terms to facilitate rapid access to its cGMP-compliant CHOSOURCE™platform for the development or production of therapeutic proteins, diagnostic assay components or vaccines relating to COVID-19. 

The CHOSOURCE platform includes a gene-edited Glutamine Synthetase (“GS”) knockout Chinese Hamster Ovary (CHO) K1 cell line, a well-established GS expression system recognized in the industry and by regulators as suitable for high yield biomanufacturing. The platform is already offered as a royalty-free alternative for the production of complex proteins and is empowering organizations from early stage start-ups to large pharmaceutical companies to drive efficiencies throughout development and production. CHOSOURCE has been utilized in multiple successful Innovative New Drug (IND) filings. 

Horizon is already a key supplier for research relating to COVID-19, providing many tools and services to academia and industry to support their efforts in addressing the pandemic. This offering further extends Horizon’s COVID-19 support portfolio.

Jesús Zurdo, Global Head Bioprocessing, Horizon Discovery said: The current coronavirus crisis is highlighting existing shortcomings in the development of much-needed therapeutics. Horizon Discovery is fully committed to help innovators in their efforts to develop new solutions to tackle the COVID-19 pandemic. We are providing immediate access to our state-of-the-art bioproduction platform under very favorable terms to facilitate such efforts.” 

Terry Pizzie, CEO, Horizon Discovery said: “We are committed to providing flexible, royalty-free access licensing terms and solutions that streamline development and production processes. Building upon more than a decade of experience in cell line engineering, we developed our CHOSOURCE cell line and now support a growing number of pharmaceutical companies in bioproduction. We are doing all that we can to support the fight against COVID-19 and hope that offering rapid access to our CHOSOURCE platform will help to accelerate the development and validation of new therapies to combat the pandemic.”